BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 25850430)

  • 21. The Symbol Digit Modalities Test is an effective cognitive screen in pediatric onset multiple sclerosis (MS).
    Charvet LE; Beekman R; Amadiume N; Belman AL; Krupp LB
    J Neurol Sci; 2014 Jun; 341(1-2):79-84. PubMed ID: 24792098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abnormal explicit but normal implicit sequence learning in premanifest and early Huntington's disease.
    Schneider SA; Wilkinson L; Bhatia KP; Henley SM; Rothwell JC; Tabrizi SJ; Jahanshahi M
    Mov Disord; 2010 Jul; 25(10):1343-9. PubMed ID: 20544716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3.
    Stout JC; Queller S; Baker KN; Cowlishaw S; Sampaio C; Fitzer-Attas C; Borowsky B;
    Mov Disord; 2014 Sep; 29(10):1281-8. PubMed ID: 25209258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of simulated driving performance in Huntington's disease.
    Jacobs M; Hart EP; Mejia Miranda Y; Groeneveld GJ; van Gerven JMA; Roos RAC
    Parkinsonism Relat Disord; 2019 Mar; 60():64-69. PubMed ID: 30292732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered driving performance of symptomatic Huntington's disease gene carriers in simulated road conditions.
    Jacobs M; Hart EP; Miranda YM; Groeneveld GJ; van Gerven JMA; Roos RAC
    Traffic Inj Prev; 2018; 19(7):708-714. PubMed ID: 30273496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington's disease mutation after 1 year.
    Lemiere J; Decruyenaere M; Evers-Kiebooms G; Vandenbussche E; Dom R
    Acta Neurol Scand; 2002 Sep; 106(3):131-41. PubMed ID: 12174172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease.
    Martinez-Horta S; Perez-Perez J; van Duijn E; Fernandez-Bobadilla R; Carceller M; Pagonabarraga J; Pascual-Sedano B; Campolongo A; Ruiz-Idiago J; Sampedro F; Landwehrmeyer GB; ; Kulisevsky J
    Parkinsonism Relat Disord; 2016 Apr; 25():58-64. PubMed ID: 26898966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postural limits of stability in premanifest and manifest Huntington's disease.
    Medina LD; Pirogovsky E; Salomonczyk D; Goldstein J; Panzera R; Gluhm S; Simmons R; Corey-Bloom J; Gilbert PE
    J Huntingtons Dis; 2013; 2(2):177-84. PubMed ID: 25063514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain metabolite alterations and cognitive dysfunction in early Huntington's disease.
    Unschuld PG; Edden RA; Carass A; Liu X; Shanahan M; Wang X; Oishi K; Brandt J; Bassett SS; Redgrave GW; Margolis RL; van Zijl PC; Barker PB; Ross CA
    Mov Disord; 2012 Jun; 27(7):895-902. PubMed ID: 22649062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. White matter connectivity reflects clinical and cognitive status in Huntington's disease.
    Poudel GR; Stout JC; Domínguez D JF; Salmon L; Churchyard A; Chua P; Georgiou-Karistianis N; Egan GF
    Neurobiol Dis; 2014 May; 65():180-7. PubMed ID: 24480090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential of composite cognitive scores for tracking progression in Huntington's disease.
    Jones R; Stout JC; Labuschagne I; Say M; Justo D; Coleman A; Dumas EM; Hart E; Owen G; Durr A; Leavitt BR; Roos R; O'Regan A; Langbehn D; Tabrizi SJ; Frost C
    J Huntingtons Dis; 2014; 3(2):197-207. PubMed ID: 25062862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease.
    Stüwe SH; Goetze O; Lukas C; Klotz P; Hoffmann R; Banasch M; Orth M; Schmidt WE; Gold R; Saft C
    Neurology; 2013 Feb; 80(8):743-6. PubMed ID: 23390182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners.
    Read J; Jones R; Owen G; Leavitt BR; Coleman A; Roos RA; Dumas EM; Durr A; Justo D; Say M; Stout JC; Tabrizi SJ; Craufurd D;
    J Huntingtons Dis; 2013; 2(2):159-75. PubMed ID: 25063513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Language disintegration in spontaneous speech in Huntington's disease: a more fine-grained analysis.
    Tovar A; Garí Soler A; Ruiz-Idiago J; Mareca Viladrich C; Pomarol-Clotet E; Rosselló J; Hinzen W
    J Commun Disord; 2020; 83():105970. PubMed ID: 32062158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the association between apathy and deficits of social cognition and executive functions in Huntington's disease.
    Hendel RK; Hellem MNN; Hjermind LE; Nielsen JE; Vogel A
    J Int Neuropsychol Soc; 2023 May; 29(4):369-376. PubMed ID: 36189712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Divergent Effects of the Nonselective Adenosine Receptor Antagonist Caffeine in Pre-Manifest and Motor-Manifest Huntington's Disease.
    Achenbach J; Matusch A; Elmenhorst D; Bauer A; Saft C
    Biomedicines; 2022 May; 10(6):. PubMed ID: 35740281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective executive dysfunction but intact risky decision-making in early Huntington's disease.
    Holl AK; Wilkinson L; Tabrizi SJ; Painold A; Jahanshahi M
    Mov Disord; 2013 Jul; 28(8):1104-9. PubMed ID: 23436289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for deficits on different components of theory of mind in Huntington's disease.
    Allain P; Havet-Thomassin V; Verny C; Gohier B; Lancelot C; Besnard J; Fasotti L; Le Gall D
    Neuropsychology; 2011 Nov; 25(6):741-51. PubMed ID: 21728429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The structural involvement of the cingulate cortex in premanifest and early Huntington's disease.
    Hobbs NZ; Pedrick AV; Say MJ; Frost C; Dar Santos R; Coleman A; Sturrock A; Craufurd D; Stout JC; Leavitt BR; Barnes J; Tabrizi SJ; Scahill RI
    Mov Disord; 2011 Aug; 26(9):1684-90. PubMed ID: 21557312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benton Judgment of Line Orientation (JoLO) Test: A Brief and Useful Measure for Assessing Visuospatial Abilities in Manifest, but not Premanifest, Huntington's Disease.
    Corey-Bloom J; Gluhm S; Herndon A; Haque AS; Park S; Gilbert PE
    J Huntingtons Dis; 2016; 5(1):91-6. PubMed ID: 27003664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.